PHARMACYTE BIOTECH, INC. (PMCB) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-07-31..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-07-31..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-07-31..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-07-31..
Free cash flow
Overview →Financial period ending 2026-07-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-3.94M | Cash generated by operating activities. Period ending 2026-07-31. |
| Operating cash flow / net income · 12 months | 0.24× | Operating cash flow / net income. Period ending 2026-07-31. $-3.94M ÷ $-16.15M ≈ 0.24× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -3.94M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | (m) | |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Revenue | 0.00 USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -16.15M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | (m) | (m) | $-3.94M | (m) | (m) | $0.00 | (m) | $-16.15M | (m) | (m) | (m) | 0.24× |
| 2026-04-30 | (m) | (m) | $-5.15M | (m) | (m) | $0.00 | (m) | $-19.42M | (m) | (m) | (m) | 0.27× |
| 2026-01-31 | (m) | (m) | $-4.80M | (m) | (m) | $0.00 | (m) | $-3.28M | (m) | (m) | (m) | 1.46× |
| 2025-10-31 | (m) | (m) | $-4.52M | (m) | (m) | $0.00 | (m) | $-7.07M | (m) | (m) | (m) | 0.64× |
| 2025-07-31 | (m) | (m) | $-4.60M | (m) | (m) | $0.00 | (m) | $-1.13M | (m) | (m) | (m) | 4.09× |
| 2025-04-30 | (m) | (m) | $-2.98M | (m) | (m) | $0.00 | (m) | $30.66M | (m) | (m) | (m) | -0.10× |
| 2025-01-31 | (m) | (m) | $-2.27M | (m) | (m) | $0.00 | (m) | $20.25M | (m) | (m) | (m) | -0.11× |
| 2024-10-31 | (m) | (m) | $-1.94M | (m) | (m) | $0.00 | (m) | $22.68M | (m) | (m) | (m) | -0.09× |
| 2024-07-31 | (m) | (m) | $-2.87M | (m) | (m) | $0.00 | (m) | $26.94M | (m) | (m) | (m) | -0.11× |
| 2024-04-30 | (m) | (m) | $-2.15M | (m) | (m) | $0.00 | (m) | $333.76K | (m) | (m) | (m) | -6.45× |
| 2024-01-31 | (m) | (m) | $-2.11M | (m) | (m) | $0.00 | (m) | $-1.14M | (m) | (m) | (m) | 1.85× |
| 2023-10-31 | (m) | (m) | $-2.47M | (m) | (m) | $0.00 | (m) | $-1.28M | (m) | (m) | (m) | 1.93× |
| 2023-07-31 | (m) | (m) | $-2.37M | (m) | (m) | $0.00 | (m) | $-5.95M | (m) | (m) | (m) | 0.40× |
| 2023-04-30 | (m) | (m) | $-3.79M | (m) | (m) | $0.00 | (m) | $-4.32M | (m) | (m) | (m) | 0.88× |
| 2023-01-31 | (m) | (m) | $-4.70M | (m) | (m) | $0.00 | (m) | $-5.61M | (m) | (m) | (m) | 0.84× |
| 2022-10-31 | (m) | (m) | $-4.45M | (m) | (m) | $0.00 | (m) | $-5.66M | (m) | (m) | (m) | 0.79× |
| 2022-07-31 | (m) | (m) | $-3.96M | (m) | (m) | $0.00 | (m) | $-4.76M | (m) | (m) | (m) | 0.83× |
| 2022-04-30 | (m) | (m) | $-4.12M | (m) | (m) | $0.00 | (m) | $-4.24M | (m) | (m) | (m) | 0.97× |
| 2022-01-31 | (m) | (m) | $-3.87M | (m) | (m) | $0.00 | (m) | $-3.78M | (m) | (m) | (m) | 1.02× |
| 2021-10-31 | (m) | (m) | $-4.16M | (m) | (m) | $0.00 | (m) | $-3.72M | (m) | (m) | (m) | 1.12× |
| 2021-07-31 | (m) | (m) | $-4.02M | (m) | (m) | $0.00 | (m) | $-3.69M | (m) | (m) | (m) | 1.09× |
| 2021-04-30 | (m) | (m) | $-3.33M | (m) | (m) | $0.00 | (m) | $-3.55M | (m) | (m) | (m) | 0.94× |
| 2021-01-31 | (m) | (m) | $-3.03M | (m) | (m) | $0.00 | (m) | $-3.34M | (m) | (m) | (m) | 0.91× |
| 2020-10-31 | (m) | (m) | $-2.79M | (m) | (m) | $0.00 | (m) | $-3.46M | (m) | (m) | (m) | 0.81× |
| 2020-07-31 | (m) | (m) | $-2.13M | (m) | (m) | $0.00 | (m) | $-3.58M | (m) | (m) | (m) | 0.59× |
| 2020-04-30 | (m) | (m) | $-2.34M | (m) | (m) | $0.00 | (m) | $-3.83M | (m) | (m) | (m) | 0.61× |
| 2020-01-31 | (m) | (m) | $-2.36M | (m) | (m) | $0.00 | (m) | $-4.22M | (m) | (m) | (m) | 0.56× |
| 2019-10-31 | (m) | (m) | $-2.68M | (m) | (m) | $0.00 | (m) | $-4.02M | (m) | (m) | (m) | 0.67× |
| 2019-07-31 | (m) | (m) | $-3.02M | (m) | (m) | $0.00 | (m) | $-3.99M | (m) | (m) | (m) | 0.76× |
| 2019-04-30 | (m) | (m) | $-2.88M | (m) | (m) | $0.00 | (m) | $-4.07M | (m) | (m) | (m) | 0.71× |
| 2019-01-31 | (m) | (m) | $-3.59M | (m) | (m) | $0.00 | (m) | $-4.22M | (m) | (m) | (m) | 0.85× |
| 2018-10-31 | (m) | (m) | $-4.09M | (m) | (m) | $0.00 | (m) | $-5.58M | (m) | (m) | (m) | 0.73× |
| 2018-07-31 | (m) | (m) | $-4.77M | (m) | (m) | $0.00 | (m) | $-6.36M | (m) | (m) | (m) | 0.75× |
| 2018-04-30 | (m) | (m) | $-5.08M | (m) | (m) | $0.00 | (m) | $-6.83M | (m) | (m) | (m) | 0.74× |
| 2018-01-31 | (m) | (m) | $-4.51M | (m) | (m) | $0.00 | (m) | $-6.69M | (m) | (m) | (m) | 0.67× |
| 2017-10-31 | (m) | (m) | $-4.26M | (m) | (m) | $0.00 | (m) | $-5.94M | (m) | (m) | (m) | 0.72× |
| 2017-07-31 | (m) | (m) | $-3.37M | (m) | (m) | $0.00 | (m) | $-5.10M | (m) | (m) | (m) | 0.66× |
| 2017-04-30 | (m) | (m) | $-3.34M | (m) | (m) | $0.00 | (m) | $-4.44M | (m) | (m) | (m) | 0.75× |
| 2017-01-31 | (m) | (m) | $-3.76M | (m) | (m) | $0.00 | (m) | $-4.41M | (m) | (m) | (m) | 0.85× |
| 2016-10-31 | (m) | (m) | $-3.84M | (m) | (m) | $0.00 | (m) | $-4.92M | (m) | (m) | (m) | 0.78× |
| 2016-07-31 | (m) | (m) | $-4.19M | (m) | (m) | $0.00 | (m) | $-5.58M | (m) | (m) | (m) | 0.75× |
| 2013-10-31 | (m) | (m) | $-587.32K | (m) | (m) | $-753.00 | (m) | $-11.03M | (m) | (m) | (m) | 0.05× |
| 2013-07-31 | (m) | (m) | $-464.71K | (m) | (m) | $5.53K | (m) | $-5.75M | (m) | (m) | (m) | 0.08× |
| 2013-04-30 | (m) | (m) | $-390.43K | (m) | (m) | $12.16K | (m) | $-1.60M | (m) | (m) | (m) | 0.24× |
| 2013-01-31 | (m) | (m) | $-299.43K | (m) | (m) | $18.84K | (m) | $-1.78M | (m) | (m) | (m) | 0.17× |
| 2012-10-31 | (m) | (m) | $-257.97K | (m) | (m) | $39.87K | (m) | $-1.67M | (m) | (m) | (m) | 0.15× |
| 2012-07-31 | (m) | (m) | $-225.05K | (m) | (m) | $53.42K | (m) | $-1.72M | (m) | (m) | (m) | 0.13× |
| 2012-04-30 | (m) | (m) | $-259.29K | (m) | (m) | $66.56K | (m) | $-1.90M | (m) | (m) | (m) | 0.14× |
| 2012-01-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-07-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-04-30 | (m) | (m) | $-225.23K | (m) | (m) | (m) | (m) | $-1.40M | (m) | (m) | (m) | 0.16× |
| 2011-01-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-07-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |